Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Idhifa (enasidenib) for the Treatment of Acute Myeloid Leukaemia (AML)

Drug (Brand / Generic)

Idhifa / enasidenib

Company / Licensee

Agios Pharmaceuticals / Celgene Corporation

Therapy Class

Isocitrate dehydrogenase 2 (IDH2) inhibitor

Current Indication

Acute myeloid leukaemia (AML)

Market Sector


Development Status

Approved in the US

Go Top